Información del artículo
Resumen
Se presenta el contenido de esta monografía sobre el conocimiento actual del ustekinumab, especialmente en relación con la psoriasis pero también en otras indicaciones. Se describe su estructura química, el proceso de obtención, se analizan los datos farmacocinéticos (absorción, distribución, metabolismo, eliminación), sus interacciones y se revisa la información relativa a la inmunogenicidad de la molécula.
Palabras clave:
Ustekinumab
Interleucina 12
Interleucina 23
Terapia biológica
Psoriasis
Enfermedad de Crohn
Farmacocinética
Abstract
This chapter opens with a brief introduction to the content of this supplement summarizing our current knowledge of ustekinumab with a particular focus on psoriasis but also including other indications. In addition to describing the chemical structure and the process used to produce this biologic agent, the chapter analyzes the drug's pharmacokinetic profile (absorption, distribution, metabolism, and excretion) and interactions with other drugs. A review of the information relating to the immunogenicity of the molecule is also included.
Keywords:
Ustekinumab
Interleukin 12
Interleukin 23
Biologic therapy
Psoriasis
Crohn disease
Pharmacokinetics
El Texto completo está disponible en PDF
Bibliografía
[1.]
F.O. Nestle, D.H. Kaplan, J. Barker.
Psoriasis.
N Engl J Med, 361 (2009), pp. 496-509
[2.]
A.B. Kimball, D. Gladman, J.M. Gelfand, K. Gordon, E.J. Horn, N.J. Korman, et al.
National Psoriasis Foundation National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening.
J Am Acad Dermatol, 58 (2008), pp. 1031-1042
[3.]
R.S. Stern, T. Nijsten, S.R. Feldman, D.J. Margolis, T. Rolstad.
Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction.
J Investig Dermatol Symp Proc, 9 (2004), pp. 136-139
[4.]
Ustekinumab SPC. (Acceso en Ago 2011). Disponible en: http://www.emea.europe.eu/humandocs/PDFs/EPAR/stelara/H-958-PI-en.pdf).
[5.]
W.J. Sandborn, B.G. Feagan, R.N. Fedorak, E. Scherl, M.R. Fleisher, S. Katz, Ustekinumab Crohn's Disease Study Group, et al.
A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease.
Gastroenterology, 135 (2008), pp. 1130-1141
[6.]
A. Gottlieb, A. Menter, A. Mendelsohn, Y.K. Shen, S. Li, C. Guzzo, et al.
Ustekinumab, a human interleukin-12/23 monoclonal antibody, for psoriatic arthritis: randomized, double-blind, placebo-controlled, crossover trial.
Lancet, 373 (2009), pp. 633-640
[7.]
L.H. Kasper, D. Everitt, T.P. Leist, K.A. Ryan, M.A. Mascelli, K. Johnson, Multiple Sclerosis Investigators, et al.
A phase I trial of an interleukin-12/23 monoclonal antibody in relapsing multiple sclerosis.
Curr Med Res Opin, 22 (2006), pp. 1671-1678
[8.]
B.M. Segal, C.S. Constantinescu, A. Raychaudhuri, L. Kim, R. Fidelus-Gort, L.H. Kasper, Ustekinumab MS Investigators.
Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomized, dose-ranging study.
Lancet Neurol, 7 (2008), pp. 796-804
[9.]
D.M. Fishwild, S.L. O’Donnell, T. Bengoechea, D.V. Hudson, F. Harding, S.L. Bernhard, et al.
High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice.
Nat Biotechnol, 14 (1996), pp. 845-851
[10.]
N. Yeilding, P. Szapary, C. Brodmerkel, J. Benson, M. Plotnick, H. Zhou, et al.
Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives.
Ann N Y Acad Sci, 1222 (2011), pp. 30-39
[11.]
J.M. Benson, C.W. Sachs, G. Treacy, H. Zhou, C.E. Pendley, C.M. Brodmerkel, et al.
Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab.
Nat Biotechnol, 29 (2011), pp. 615-624
[12.]
Y. Zhu, C. Hu, M. Lu, S. Liao, J.C. Marini, J. Yohrling, et al.
Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis.
J Clin Pharmacol, 49 (2009), pp. 162-175
[13.]
Y.W. Zhu, A. Mendelsohn, C. Pendley, H.M. Davis, H. Zhou.
Population pharmacokinetics of ustekinumab in patients with active psoriatic arthritis.
Int J Clin Pharmacol Ther, 48 (2010), pp. 830-846
[14.]
K. Reich.
Ustekinumab for the treatment of plaque psoriasis.
Expert Rev Dermatol, 4 (2009), pp. 443-453
[15.]
A.B. Gottlieb, K.D. Cooper, T.S. McCormick, E. Toichi, D.E. Everitt, B. Frederick, et al.
A phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasis.
Curr Med Res Opin, 23 (2007), pp. 1081-1092
[16.]
V. Ghetie, E.S. Ward.
Transcytosis and catabolism of antibody.
Immunol Res, 25 (2002), pp. 97-113
[17.]
M. Lebwohl, N. Yeilding, P. Szapary, Y. Wang, S. Li, Y. Zhu, et al.
Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendations.
J Am Acad Dermatol, 63 (2010), pp. 571-579
[18.]
H. Zhou.
Population-based assessments of clinical drug-drug interactions: qualitative indices or quantitative measures?.
J Clin Pharmacol, 46 (2006), pp. 1268-1289
[19.]
H. Zhou, H.M. Davis.
Risk-based strategy for the assessment of pharmacokinetic drug-drug interactions for therapeutic monoclonal antibodies.
Drug Discov Today, 14 (2009), pp. 891-898
[20.]
C.L. Leonardi, A.B. Kimball, K.A. Papp, N. Yeilding, C. Guzzo, Y. Wang, PHOENIX 1 study investigators, et al.
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomized, double-blind, placebo-controlled trial (PHOENIX 1).
Lancet, 371 (2008), pp. 1665-1674
[21.]
K.A. Papp, R.G. Langley, M. Lebwohl, G.G. Krueger, P. Szapary, N. Yeilding, PHOENIX 2 study investigators, et al.
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomized, double-blind, placebo-controlled trial (PHOENIX 2).
Lancet, 371 (2008), pp. 1675-1684
[22.]
C.E. Griffiths, B.E. Strober, P. Van de Kerkhof, V. Ho, R. Fidelus-Gort, N. Yeilding, ACCEPT Study Group, et al.
Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis.
N Engl J Med, 362 (2010), pp. 118-128
[23.]
C.L. Kauffman, N. Aria, E. Toichi, T.S. McCormick, K.D. Cooper, A.B. Gottlieb, et al.
A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis.
J Invest Dermatol, 123 (2004), pp. 1037-1044
[24.]
G.G. Krueger, R.G. Langley, C. Leonardi, N. Yeilding, C. Guzzo, Y. Wang, CNTO 1275 Psoriasis Study Group, et al.
A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis.
N Engl J Med, 356 (2007), pp. 580-592
Copyright © 2012. Academia Española de Dermatología y Venereología
